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1.6 cm) when compared to a healthy reference population 
(girls 19.0  8 3.9 cm and boys 18.7  8 4.7 cm). At the age of 3 
years, bone age was appropriate for chronological age in 
both girls (2.7  8 0.5 years) and boys (2.9  8 0.5 years).  Con-
clusion: Birth length is above average in children with clas-
sical CAH, which might be the result of untreated hyperan-
drogenism in utero. With relatively low doses of hydrocorti-
sone treatment, growth velocity decreases slightly during 
the first 9 months and H-SDS then approaches the genetic 
height potential.  Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 Congenital adrenal hyperplasia (CAH) is caused by 
the loss or severe decrease in activity in 1 of the 5 ste-
roidogenic enzymes involved in cortisol biosynthesis. In 
over 90% of all cases, 21-hydroxylase deficiency is found 
 [1] . It is caused by mutations in the 21-hydroxylase gene 
 CYP21A2 , which is located in the human leukocyte anti-
gen (HLA) gene cluster region on the short arm of chro-
mosome 6 (6p21.3)  [2] . The disease is divided on clinical 
grounds into the classical and the nonclassical forms. 
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 Abstract 
 Background: Linear growth is the best clinical parameter for 
monitoring metabolic control in classical congenital adrenal 
hyperplasia (CAH).  Objective: To analyze growth patterns in 
children with CAH diagnosed by newborn screening and 
treated with relatively low doses of hydrocortisone during 
the first year of life.  Patients and Methods: 51 patients (27 
females) were diagnosed with classical CAH by newborn 
screening. All patients were treated with relatively low doses 
of hydrocortisone (9–15 mg/m 2 body surface area). 47 pa-
tients were additionally treated with fludrocortisone.  Re-
sults: At birth, height SDS (H-SDS) was 1.1  8 1 in girls and 0.9 
 8 1.5 in boys. After 3 months, H-SDS decreased to 0.4  8 0.9 
in girls and to 0.1  8 1.3 in boys. Over the 3-year period, H-
SDS further decreased to –0.4  8 1.8 in girls and to –0.8  8 1 
in boys and approached the genetic height potential (target 
H-SDS of girls –0.5  8 0.3 and target H-SDS of boys –0.9  8 
0.7). During the first 9 months of age, growth velocity was 
slightly decreased in girls (18.2  8 1.9 cm) and boys (17.3  8 
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There are different degrees of severity of the same enzy-
matic deficiency in these two forms of the disease. The 
worldwide incidence of classical 21-hydroxylase deficien-
cy is approximately 1 in 14,000 births  [3] . Therefore, car-
rier frequency of this autosomal recessive disease is about 
1 in 60. 21-hydroxylase deficiency leads to accumulation 
of 17-hydroxyprogesterone and results in increased pro-
duction of adrenal androgens and decreased production 
of cortisol. In addition to impaired cortisol biosynthesis, 
aldosterone production may be decreased as well (salt-
wasting CAH). In simple virilizing CAH, there is viriliza-
tion of external genitalia in newborn females and pseu-
doprecocious puberty due to overproduction of andro-
gens in both sexes. In salt-wasting CAH, additional severe 
renal salt loss occurs as a consequence of aldosterone de-
ficiency. Overproduction of androgens causes viriliza-
tion, accelerated growth, advanced skeletal maturation 
and early epiphyseal fusion. While the various forms of 
CAH differ in their degree of enzymatic deficiency, they 
all represent a therapeutic challenge to pediatric endocri-
nologists attempting to optimize growth.
 Traditional treatment consists of the suppression of 
ACTH through glucocorticoid replacement, in attempt to 
reduce excessive androgen production and its conse-
quences. Low-dose treatment with glucocorticoids may 
result in androgen excess with advancement of bone age 
and a reduced final height. In overtreatment, growth is 
suppressed by the growth inhibiting effects of glucocor-
ticoids. Further side effects of overtreatment are truncal 
obesity and osteoporosis. Alternate approaches to the 
treatment of CAH have been investigated recently, in-
cluding the use of antiandrogens, aromatase inhibitors 
and adrenalectomy  [4] . However, the mainstay of therapy 
remains judicious glucocorticoid treatment along with 
careful monitoring of growth velocity and skeletal matu-
ration, along with urine, serum and salivary steroid hor-
mone levels  [5] .
 Since newborn screening is available nowadays, diag-
nosis of CAH is no longer delayed. There is some evidence 
that infants with CAH are relatively androgen-insensitive 
during the first year of life  [6] . Thus, it seems reasonable 
and ethical to treat infants with CAH with lower doses of 
hydrocortisone during that period.
 Patients and Methods 
 In Bavaria, newborn screening for CAH started on January 1, 
1999. Since then, 51 patients (27 females, 24 males) diagnosed 
with classical CAH due to 21-hydroxylase deficiency were re-
ferred to our institution. The diagnosis of 21-hydroxylase defi-
ciency was confirmed by genotyping in all patients (5 patients 
with homozygous deletion of the whole gene, 15 patients with de-
letion of one gene and mutation of second gene, 7 patients with 
conversion of one gene and mutation of second gene, 24 patients 
with compound heterozygous mutations;  table 1 ). The diagnosis 
was also reconfirmed by hormonal analysis (low cortisol and el-
evated 17-hydroxyprogesterone concentration). During the first 6 
months of life, all patients were treated with 1 mg of hydrocorti-
sone 3 times daily and 0.05 mg of fludrocortisone 2 or 3 times 
daily. Thereafter, hydrocortisone doses were individually in-
creased and the fludrocortisone dose was reduced. When plasma 
renin activity rose  1 18 ng/ml/h after reduction of fludrocortisone 
during the first 6 months of life or  1 8 ng/ml/h after 6 months of 
life, fludrocortisone was increased and patients were assumed to 
have the salt-wasting form of CAH. All patients were continu-
ously cared for in our clinic, with follow-up appointments every 
3 months during the first 2 years of life, and every 6 months there-
after.
 Adjustment of the glucocorticoid dose was made using auxo-
logical data (goal: linear growth as best clinical parameter of met-
abolic control) and hormonal data (treatment goals: morning se-
rum 17-hydroxyprogesterone  ! 18 nmol/l and plasma renin activ-
ity  ! 18 ng/ml/h until 6 months of age,  ! 5.5 ng/ml/h above the age 
of 6 months). These cutoffs were determined using age and sex-
specific normative data for assays at the own endocrine labora-
tory. When enough serum was available, androstenedione and 
testosterone were measured as well, but these parameters were not 
available for all patients at all times and were therefore excluded 
from the analysis. Until the age of 2 years, height was measured 
in a lying position using a pediatric measuring device (infantom-
eter); after 2 years of age, height was measured in a standing posi-
tion using a digital telescopic wall-mounted stadiometer (Ulmer 
Stadiometer). Height standard deviation scores (H-SDS) were cal-
culated with a growth calculator, using reference data from Prad-
er et al.  [7] which are used in the ‘Alpine’ region of Europe (Swit-
zerland, Austria, Southern Germany). Height was compared with 
matched controls among healthy children with the same birth 
years. Controls were recruited from an outpatient pediatrician. In 
Germany, children have regular check-ups at their pediatrician 
and height, weight and head circumference are documented in a 
little yellow booklet.
 Weight was determined to the nearest of 0.1 kg using an elec-
tronic scale (Seca 753 E). Body mass index (BMI) was calculated 
as weight (kg)/height (m 2 ) and BMI-SDS was derived from data 
published by Cole et al.  [8] .
 Bone age was assessed at the age of 3 years by X-ray of the left 
hand using the Greulich and Pyle method  [9] . Bone age was read 
by both an experienced pediatric endocrinologist and a radiolo-
gist, who both agreed on the result of each other’s reading after 
discussing the X-ray.
 Most parental heights were asked and available on all patients. 
Parental heights could not be measured in all parents because 
both parents were not present in most cases. When asked for, pa-
rental heights mostly result in overestimation, especially among 
fathers, which has to be taken into account. The genetic target 
height was calculated as midparental height (the mean of the two 
parents’ heights) plus 6.5 cm for boys and minus 6.5 cm for girls.
 Statistical analyses were performed with the nonparametric 
Wilcoxon test and for group comparisons with the nonparametric 
Mann-Whitney U test.
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 Statistical analyses were done with the SPSS 10.0 software 
(2002; SPSS Inc., Chicago, Ill, USA). p  ! 0.05 was considered sta-
tistically significant.
 Results 
 The majority of patients were diagnosed with salt-
wasting CAH and only 4 patients were classified as simple 
virilizing CAH. At birth, H-SDS related to gestational age 
was 1.1  8 1 in girls, and 0.9  8 1.5 in boys, respectively. 
Accordingly, the birth length of both girls and boys with 
classical CAH was significantly increased when com-
pared with healthy controls. After 3 months, H-SDS de-
creased significantly to 0.4  8 0.9 SDS in girls (p  ! 0.01) 
and to 0.1  8 1.3 SDS in boys (p  ! 0.01). At 1 year of age, 
H-SDS further decreased to –1.1  8 1.8 SDS in girls and 
–0.9  8 0.9 SDS in boys (p  ! 0.01). After 3 years, H-SDS 
was –0.4  8 1.8 SDS in girls and –0.8  8 1 SDS in boys, 
and approached the genetic height potential (target H-
SDS of girls: –0.5  8 0.3, target H-SDS of boys: –0.9  8 0.7; 
 table 2 ,  fig. 1 ).
 During the first 9 months of age, growth velocity was 
subnormal in girls (18.2  8 1.9 cm) and boys (17.3  8 1.6 
cm) when compared to a healthy reference population 
(girls: 19.0  8 3.9 cm, boys: 18.7  8 4.7 cm, Prader et al. 
 [7] , p  ! 0.05). During the second and third year of life, 
growth velocity was in the normal range (growth veloc-
ity second year: CAH girls 11.9  8 1.4 cm, CAH boys 12 
 8 1.7 cm vs. reference girls 11.1  8 2 cm and reference 
Table 1. G enotype/phenotype of the study group
Patient Sex Genotype Phenotype
1 M del del SW
2 M del del SW
3 M del del SW
4 M I2G del SW
5 M I2G R356W SW
6 M I172N I172N SW
7 M I2G I172N SV
8 M I2G I160N SW
9 M I2G I2G SW
10 M Q318X Q318X SW
11 M I2G I2G SW
12 M del I2G SW
13 M del Q318X SW
14 M I2G I2G SV
15 M del I2G SW
16 M I2G del SW
17 M I2G ? SW
18 M I172N conv SW
19 M I2G I172N SW
20 M I2G del SW
21 M I2G del SW
22 M I2G I2G SW
23 M I2G I2G SW
24 M del I2G SW
25 F I172N I2G SW
26 F I2G I2G SW
27 F I2G I2G SW
28 F I172N conv SW
29 F I172N conv SW
30 F I2G conv SW
31 F I2G conv SW
32 F I172N I172N SW
33 F I172N Q474X SV
34 F I2G I2G SW
35 F I2G del SW
36 F I2G del SW
37 F I172N I2G SW
38 F del I172N SW
39 F I2G I172N SW
40 F del I2G SW
41 F I2G conv SW
42 F I2G conv SW
43 F del del SW
44 F del I2G SW
45 F I2G I172N SW
46 F I2G I2G SW
47 F I172N R356W SW
48 F I2G del SW
49 F del W204X SW
50 F del del SW
51 F R356W I172N SV
del = Deletion; conv = conversion, I2G = intron 2 splice site 
mutation; SW = salt-wasting; SV = simple virilizing.
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 Fig. 1. Growth pattern of CAH patients: course of H-SDS. Black 
line with boxes: girls. Grey line with boxes: boys. Black line with 
triangles: reference group. Black arrow: target height girls (mean 
 8 1 SD); grey arrow: target height boys (mean  8 1 SD). 
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boys 11.0  8 3.5 cm; growth velocity third year: CAH girls 
8.6  8 1.4 cm, CAH boys 8.1  8 2 cm vs. reference girls 
8.5  8 1.5 cm and reference boys 8.3  8 1.3 cm;  table 3 ).
 With hydrocortisone substitution in the low range of 
general treatment recommendations  [10] (1 mg of hydro-
cortisone 3 times daily during the first 6 months, corre-
sponding to approximately 10 mg of hydrocortisone per 
m 2 body surface area), in girls the mean plasma 17-hy-
droxyprogesterone concentration was still elevated at 3 
months and subsequently decreased to the treatment goal 
 ! 18 nmol/l. With the same treatment regimen in boys, 
the 17-hydroxyprogesterone concentration was elevated 
at 3 and at 6 months of age and decreased to a mean con-
centration of 10.2 nmol/l at the age of 9 months. Over 3 
years, the mean hydrocortisone substitution dose ranged 
between 9.3 and 12.8 mg per m 2 body surface area ( ta-
ble 2 ). One patient suffered from adrenal crisis in the con-
text of gastroenteritis while failing to increase hydrocor-
tisone dose.
 At the age of 3 years, bone age was appropriate for 
chronological age in both girls (2.7  8 0.5 years) and boys 
(2.9  8 0.5 years), indicating that the relatively low dosage 
of hydrocortisone during the first 6 months did not lead 
to accelerated bone age.
 At 3 months of age, BMI-SDS was 0.1  8 1.7 in girls 
and –0.3  8 1.6 in boys. BMI-SDS remained around the 
mean over the study period (BMI-SDS at 3 years: 0  8 1 
SDS in girls vs. –0.1  8 1.1 SDS in boys;  table 1 ).
 Discussion 
 Since newborn screening is available nowadays, diag-
nosis of CAH is no longer delayed and optimal treatment 
strategies during the first months of life have become 
more important.
 According to the consensus statement on 21-hydroxy-
lase deficiency from the Lawson Wilkins Pediatric Endo-
Table 2. L ongitudinal data on H-SDS, BMI-SDS, hydrocortisone dose and 17-OH-progesterone (mean 8 1 SD)
Birth 3 months 6 months 9 months 12 months 18 months 24 months 36 months Target
H-SDS
Bone age at 
36 months 
years
Girls (n = 27)
H-SDS 1.181 0.480.9* –0.581.2* –0.881.2* –1.181.8* –1.381.4* –0.981.2* –0.481.8* –0.580.3 2.780.5
BMI-SDS 0.181.7 –0.381.4 –0.481.3 –0.381.3 –0.380.7 0.180.8 081
HC dose, mg/m2 10.282.3 10.383.8 9.681.6 10.582.2 10.982.6 11.182.1 12.881.9
17-OH-progesterone, nmol/l 29.9831 10811 7.787.5 7.786 6.787.9 20836 4.785.5
Boys (n = 24)
H-SDS 0.981.5 0.181.3* –0.681.2* –0.680.9* –0.980.9* –0.881.1* –0.680.9* –0.881* –0.980.7 2.980.5
BMI-SDS –0.381.6 –0.681.4 –0.781.5 –0.581.5 –0.581.4 –0.581.3 –0.181.1
HC dose, mg/m2 10.883.2 1083.2 9.382 9.682.3 10.481.9 11.381.7 12.181.6
17-OH-progesterone, nmol/l 78.68117 26.3839 10.288 12.5818 10.686.7 6.488.6 17850
H -SDS decreases significantly compared to H-SDS at birth (* p < 0.05) in boys and girls with CAH. HC = Hydrocortisone.
Table 3. G rowth velocity at 9 months, 2 and 3 years of age (mean 8 1 SD)
CAH patients Reference population [7]
Growth velocity during first 9 months, cm/year females 18.281.9 19.083.9*
males 17.381.6 18.784.7*
Growth velocity at 2 years, cm/year females 11.981.4 11.182.0
males 12.081.7 11.083.5
Growth velocity at 3 years, cm/year females 8.681.4 8.581.5
males 8.182.0 8.381.3
C AH patients compared to a healthy reference population (* p < 0.05).
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crine Society and The European Society for Pediatric En-
docrinology, typical hydrocortisone doses during infan-
cy range between 10 and 15 mg/m 2 body surface area, but 
higher doses up to 25 mg/m 2 body surface area may be 
necessary initially  [10] .
 From the observation of growth patterns of untreated 
boys with delayed diagnosis of simple virilizing CAH in 
the pre-newborn screening era, it has been hypothesized 
that infants are relatively insensitive to androgen excess 
 [11] . In another synopsis of 17 untreated patients with 
simple virilizing CAH, growth velocity was not increased 
during the first year of life. After that period, a progres-
sive increase in height velocity and bone maturation was 
observed  [6] . Therefore, lower doses of hydrocortisone 
may be sufficient during the first months of life in terms 
of growth. For this reason we accepted suboptimal hor-
monal control of CAH at the age of 3 months and contin-
ued hydrocortisone substitution at the low end of thera-
peutic recommendations  [10] . Even though metabolic 
control was definitely not too tight, H-SDS decreased sig-
nificantly during the first 6 months of life, indicating 
again that infants are not very sensitive to androgens but 
may be extremely sensitive to glucocorticoid treatment in 
terms of growth inhibition. Also during the first 9 months 
of age, growth velocity was decreased when compared to 
healthy controls, which might have resulted from the 
growth suppressing effects of glucocorticoid treatment. 
Therefore, our relatively low hydrocortisone dose might 
still be too high during the first year of life. On the other 
hand, with hydrocortisone substitution at the low end of 
therapeutic recommendations  [10] , we do not believe that 
decreased growth velocity was caused by a glucocorticoid 
deficient state since only 1 patient suffered from adrenal 
crisis in the context of gastroenteritis while failing to in-
crease hydrocortisone dose. The fact that H-SDS in the 
target H-SDS range is reached between the ages of 1 and 
3 years suggests that hydrocortisone substitution was suf-
ficient. Another indicator for adequate hydrocortisone 
substitution in our patients was the age-appropriate bone 
age at 3 years. The vast majority of patients in our study 
were classified as having salt-wasting CAH. This is some-
what unusual and may partially explain lower hydrocor-
tisone requirements because patients were additionally 
treated with fludrocortisone.
 In our cohort, birth length was above average in both 
boys and girls with classical CAH. Significantly increased 
birth length was also observed in an Italian and Finnish 
population with classical CAH  [12, 13] . Among the pa-
tients with classical CAH, those with the salt-wasting 
form were longer but weighed less than those with the 
simple virilizing form  [12] . Worldwide, healthy males are 
known to be heavier than healthy females at term birth. 
This difference is at least partially explained by androgen 
action in utero  [14] . Androgens appear to affect the 
growth of bone cells, acting both directly and indirectly 
through the IGF-1 system  [15, 16] . Increased expression 
of IGF-1 and IGF-BP3 mRNA as well as increased IGF-1 
and IGF-BP3 concentration were observed after treat-
ment of human osteoblasts with dihydrotestosterone  [17] . 
Interestingly, in our cohort of CAH infants, the birth 
length of girls was greater than the birth length of boys.
 We found H-SDS to decrease significantly during the 
first year of life in girls and boys with classical CAH. This 
result is comparable to that of a multicenter study by Har-
gitai et al.  [18] who observed a decline of the general 
growth trendline to the 10th centile by the age of 1.5 years 
in girls and boys with salt-wasting CAH.
 With relatively high doses of hydrocortisone (19.6–
28.2 mg/m 2 /day) during the first 2 years of life, Manoli et 
al.  [19] found a negative correlation between hydrocorti-
sone dose and height at 2 years (r = –0.79) in patients with 
salt-wasting CAH diagnosed within the first 2 months of 
life. Mean height at 2 years was –0.33 SDS in girls and 
+0.45 SDS in boys. Moreover, height at 2 years showed a 
positive correlation to final height in this rather timely 
diagnosed subset of patients.
 In a retrospective analysis of the growth inhibiting ef-
fects of glucocorticoid treatment in salt-wasting CAH, 
Stikkelbroeck et al.  [20]  found that in the interval be-
tween 6 and 12 months and between 8 and 14 years of age, 
there is a dose-dependent negative effect of glucocorti-
coids on linear growth. Weight and weight for height 
were not significantly influenced by glucocorticoid dose 
at any age. The authors conclude that the daily glucocor-
ticoid dose during these intervals has to be adjusted care-
fully to allow optimal linear growth and adult height.
 In summary, we were able to identify a typical growth 
pattern of patients with classical CAH diagnosed by new-
born screening and treated with relatively low doses of 
hydrocortisone. Suboptimal hormonal control at 3 or 6 
months of age does not seem to accelerate bone age and 
growth due to relative androgen insensitivity of infants at 
that age. With hydrocortisone substitution between 9 and 
15 mg per m 2 body surface area per day, patients were able 
to achieve H-SDS in the target height range. 
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